Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-surgical pembrolizumab before second evacuation for low-risk post-molar gestational trophoblastic neoplasia
ISRCTN86152317Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial in trophoblastic tumour comparing Standard of care second evacuation with Neoadjuvant pembrolizumab plus second evacuation (2 arms). Primary endpoints: Proportion of eligible patients who consent to randomisation and Proportion of patients randomised to the intervention arm who complete protocol treatments. Started Feb 2024; status: recruiting.
02
Drugs
03
Conditions
trophoblastic tumour
Beyond the preview
Go deeper on ISRCTN86152317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN86152317.